|
|
|
| Expression of CDKN2A Gene in Lung Cancer and Its Clinical Significance |
| ZHOU Xiaoyu, CHANG Jie, WANG Erxiao, et al |
| The First Affiliated Hospital of PLA Air Force Military Medical University, Shanxi Xi'an 710032, China |
|
|
|
|
Abstract Objective: To investigate the expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene in lung cancer tissue and its relationship with pathological characteristics and prognosis.Methods: The clinical pathological data and follow-up data of 81 patients with lung cancer who were admitted to the hospital between January and December 2017 were retrospectively analyzed. Paraffin-embedded lung cancer tissues and adjacent tissues (about 2 cm from the edge of the cancer tissue) were collected from all the subjects. Immunohistochemical staining of CDKN2A in lung cancer and its adjacent tissues was observed. The relative expression levels of CDKN2A mRNA and CDKN2A protein in lung cancer and its adjacent tissues were compared. According to the expression level of CDKN2A in lung cancer, the subjects were divided into the high expression group and the low expression group. The two-year follow-up survival rate was compared between the two groups. Results: The expression rate of CDKN2A in lung cancer tissues was significantly lower than that in adjacent tissues (P<0.05). The relative expression levels of CDKN2A mRNA and CDKN2A protein in lung cancer tissues were significantly lower than those in adjacent tissues (P<0.05). The high expression rates of CDKN2A in patients with high differentiation degree and without lymph node metastasis were significantly higher than those with low differentiation degree and lymph node metastasis (P<0.05). The follow-up results showed that the 2-year survival rate of the high expression group [100.00% (8/8)] was significantly higher than that of the low expression group [65.67% (44/67)] (Log rank test value = 5.024, P<0.05). Conclusion: The expression of CDKN2A gene is low in lung cancer tissues, and its expression is closely related to the pathological characteristics and prognosis of patients with lung cancer, which can provide a reference for early diagnosis and treatment of lung cancer.
|
|
|
|
|
|
[1] 杨澜,陈勃江,李镭,等.循环肿瘤DNA甲基化在非小细胞肺癌中的研究进展[J].中华结核和呼吸杂志,2018,41(12):967~970.
[2] Fanelie Jouenne,Isaure Chauvot de Beauchene,Emeline Bollaert,et al.Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma[J].Journal of Medical Genetics,2017,54(9):607~612.
[3] Hideyuki Hayashi,Takashi Kohno,Hideki Ueno,et al.Utility of assessing the number of mutated KRAS,CDKN2A,TP53,and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic cancer[J].Pancreas,2017,46(3):335~340.
[4] 魏伦收,姚坤厚,索智敏,等.过表达细胞周期蛋白依赖性激酶2A基因抑制食管癌TE-13细胞增殖[J].中华实验外科杂志,2018,35(5):865~867.
[5] 江悦,宋国新,张炜明,等.两种免疫组织化学平台和抗体检测PD-L1表达的一致性分析[J].中华病理学杂志,2019,48(11):867~872.
[6] 王鑫,刘也夫,尚海,等.帕博西林治疗CDKN2A基因缺失胰腺癌1例[J].临床军医杂志,2018,46(7):851.
[7] 梅新宇.CHFR,CDKN2A甲基化在食管鳞癌中的表达及其在放射抵抗中的作用研究[D].山东大学,2015.
[8] Anna D Panani,Katerina Maliaga,Athanasia Babanaraki,et al.Numerical abnormalities of chromosome 9 and p16(CDKN2A) gene deletion detected by FISH in non-small cell lung cancer[J].Anticancer Research,2009,29(11):4483~4487.
[9] Chongchang Zhou,Jinyun Li,Qun Li.CDKN2A methylation in esophageal cancer:A meta-analysis[J].Oncotarget,2017,8(30):50071~50083.
[10] 方红.CDKN2A基因在非小细胞肺癌中表达及生物学功能生物信息分析[J].临床肺科杂志,2020,25(2):196~200.
[11] Xande J G,Dias A P,Tamura R E,et al.Bicistronic transfer of CDKN2A and p53 culminates in collaborative killing of human lung cancer cells in vitro and in vivo[J].Gene Therapy,2019,27(9).
[12] 侯彬.Ⅱ-Ⅲ期小细胞肺癌患者术后回顾性生存分析[D].山东大学,2017.
[13] Melanie Spitzwieser,Elisabeth Entfellner,Bettina Werner,et al.Hypermethylation of CDKN2A exon 2 in tumor,tumor-adjacent and tumor-distant tissues from breast cancer patients[J].Bmc Cancer,2017,17(1):260~261. |
|
|
|
2021, Vol. 27 
